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We read with interest the commentary by Hoff mann and 
colleagues [1] on our manuscript recently published in 
Critical Care showing that matrix metalloproteinase 
(MMP)-9, MMP-10 and tissue inhibitor of matrix 
metalloproteinases (TIMP)-1 could be new biomarkers of 
severity and mortality in sepsis [2]. As they stated, the 
lack of serial measurements of MMPs and TIMPs over 
clinical evolution was as a limitation of our study. Despite 
this limitation, our results suggest that MMPs and TIMPs 
may be of pathophysiological signifi cance in sepsis.
Some clinical studies have found higher circulating 
levels of MMP-9 [2-4] and TIMP-1 [2,3] in septic patients 
than in healthy controls, and higher levels of TIMP-1 
[2,3] or MMP-9 [4] in nonsurviving than in surviving 
septic patients. Our study also reports, for the fi rst time, 
that MMP-10 circulating levels are also elevated in septic 
patients [2]. According to the results of some in vitro
studies, MMP-10 could play a role in infection, since 
increased MMP-10 gene transcription was observed after 
infective stimulation of human and mice cells.
On the other hand, we think the correlation between 
MMP-9, TIMP-1 and markers of coagulopathy, and the 
lower MMP-9/TIMP-1 ratio in nonsurviving than in 
surviv ing septic patients found in our study, may be 
associated with a higher prothrombotic/antifi brinolytic 
state, responsible for the capillary thrombosis, multiple 
organ dysfunction, and death.
Finally, from a therapeutic perspective, the develop-
ment of modulators of MMP/TIMP activity could be 
used as a new class of drugs for the treatment of severe 
sepsis [5].
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